vs
Side-by-side financial comparison of CSW INDUSTRIALS, INC. (CSW) and Travere Therapeutics, Inc. (TVTX). Click either name above to swap in a different company.
CSW INDUSTRIALS, INC. is the larger business by last-quarter revenue ($233.0M vs $129.7M, roughly 1.8× Travere Therapeutics, Inc.). On growth, Travere Therapeutics, Inc. posted the faster year-over-year revenue change (73.4% vs 20.3%). Over the past eight quarters, Travere Therapeutics, Inc.'s revenue compounded faster (77.0% CAGR vs 5.1%).
Travere Therapeutics, Inc. is a global biopharmaceutical firm developing and commercializing innovative therapies for patients with rare, serious, life-threatening diseases. Its key segments cover rare nephrology, hepatology and metabolic disorders, serving markets across North America, Europe and other global regions.
CSW vs TVTX — Head-to-Head
Income Statement — Q3 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $233.0M | $129.7M |
| Net Profit | $10.3M | — |
| Gross Margin | 39.7% | 98.0% |
| Operating Margin | 7.4% | -25.0% |
| Net Margin | 4.4% | — |
| Revenue YoY | 20.3% | 73.4% |
| Net Profit YoY | -61.9% | — |
| EPS (diluted) | $0.62 | $0.04 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $233.0M | $129.7M | ||
| Q3 25 | $277.0M | $164.9M | ||
| Q2 25 | $263.6M | $114.4M | ||
| Q1 25 | $230.5M | $81.7M | ||
| Q4 24 | $193.6M | $74.8M | ||
| Q3 24 | $227.9M | $62.9M | ||
| Q2 24 | $226.2M | $54.1M | ||
| Q1 24 | $210.9M | $41.4M |
| Q4 25 | $10.3M | — | ||
| Q3 25 | $40.7M | $25.7M | ||
| Q2 25 | $40.9M | $-12.8M | ||
| Q1 25 | $35.1M | $-41.2M | ||
| Q4 24 | $26.9M | — | ||
| Q3 24 | $36.1M | $-54.8M | ||
| Q2 24 | $38.6M | $-70.4M | ||
| Q1 24 | $31.8M | $-136.1M |
| Q4 25 | 39.7% | 98.0% | ||
| Q3 25 | 43.0% | 99.0% | ||
| Q2 25 | 43.8% | 98.7% | ||
| Q1 25 | 44.2% | 94.3% | ||
| Q4 24 | 41.4% | 96.6% | ||
| Q3 24 | 45.6% | 97.4% | ||
| Q2 24 | 47.5% | 96.2% | ||
| Q1 24 | 44.4% | 96.4% |
| Q4 25 | 7.4% | -25.0% | ||
| Q3 25 | 20.5% | 15.1% | ||
| Q2 25 | 20.8% | -11.1% | ||
| Q1 25 | 19.5% | -52.2% | ||
| Q4 24 | 15.3% | -81.2% | ||
| Q3 24 | 22.6% | -89.3% | ||
| Q2 24 | 24.3% | -125.1% | ||
| Q1 24 | 21.0% | -336.5% |
| Q4 25 | 4.4% | — | ||
| Q3 25 | 14.7% | 15.6% | ||
| Q2 25 | 15.5% | -11.1% | ||
| Q1 25 | 15.2% | -50.4% | ||
| Q4 24 | 13.9% | — | ||
| Q3 24 | 15.8% | -87.1% | ||
| Q2 24 | 17.1% | -130.1% | ||
| Q1 24 | 15.1% | -328.9% |
| Q4 25 | $0.62 | $0.04 | ||
| Q3 25 | $2.41 | $0.28 | ||
| Q2 25 | $2.43 | $-0.14 | ||
| Q1 25 | $2.05 | $-0.47 | ||
| Q4 24 | $1.60 | $-0.71 | ||
| Q3 24 | $2.26 | $-0.70 | ||
| Q2 24 | $2.47 | $-0.91 | ||
| Q1 24 | $2.03 | $-1.76 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $40.2M | $93.0M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $1.1B | $114.8M |
| Total Assets | $2.3B | $605.2M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $40.2M | $93.0M | ||
| Q3 25 | $31.5M | $110.9M | ||
| Q2 25 | $38.0M | $75.2M | ||
| Q1 25 | $225.8M | $61.9M | ||
| Q4 24 | $213.8M | $58.5M | ||
| Q3 24 | $273.2M | $36.4M | ||
| Q2 24 | $18.9M | $32.3M | ||
| Q1 24 | $22.2M | $43.3M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | $800.1M | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | $166.0M | — |
| Q4 25 | $1.1B | $114.8M | ||
| Q3 25 | $1.1B | $73.6M | ||
| Q2 25 | $1.1B | $32.7M | ||
| Q1 25 | $1.1B | $32.8M | ||
| Q4 24 | $1.0B | $59.1M | ||
| Q3 24 | $1.0B | $-30.5M | ||
| Q2 24 | $650.2M | $15.1M | ||
| Q1 24 | $615.7M | $74.1M |
| Q4 25 | $2.3B | $605.2M | ||
| Q3 25 | $1.5B | $538.6M | ||
| Q2 25 | $1.5B | $555.3M | ||
| Q1 25 | $1.4B | $548.8M | ||
| Q4 24 | $1.4B | $594.1M | ||
| Q3 24 | $1.4B | $504.4M | ||
| Q2 24 | $1.1B | $551.1M | ||
| Q1 24 | $1.0B | $663.5M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | 0.75× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 0.27× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $28.9M | $60.7M |
| Free Cash FlowOCF − Capex | $22.7M | — |
| FCF MarginFCF / Revenue | 9.8% | — |
| Capex IntensityCapex / Revenue | 2.6% | — |
| Cash ConversionOCF / Net Profit | 2.81× | — |
| TTM Free Cash FlowTrailing 4 quarters | $162.0M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $28.9M | $60.7M | ||
| Q3 25 | $61.8M | $14.3M | ||
| Q2 25 | $60.6M | $5.0M | ||
| Q1 25 | $27.3M | $-42.2M | ||
| Q4 24 | $11.6M | $-35.7M | ||
| Q3 24 | $66.8M | $-42.5M | ||
| Q2 24 | $62.7M | $-40.2M | ||
| Q1 24 | $22.4M | $-119.0M |
| Q4 25 | $22.7M | — | ||
| Q3 25 | $58.7M | $14.2M | ||
| Q2 25 | $57.7M | — | ||
| Q1 25 | $22.8M | — | ||
| Q4 24 | $8.5M | — | ||
| Q3 24 | $61.3M | — | ||
| Q2 24 | $59.6M | $-40.3M | ||
| Q1 24 | $17.5M | — |
| Q4 25 | 9.8% | — | ||
| Q3 25 | 21.2% | 8.6% | ||
| Q2 25 | 21.9% | — | ||
| Q1 25 | 9.9% | — | ||
| Q4 24 | 4.4% | — | ||
| Q3 24 | 26.9% | — | ||
| Q2 24 | 26.3% | -74.5% | ||
| Q1 24 | 8.3% | — |
| Q4 25 | 2.6% | — | ||
| Q3 25 | 1.1% | 0.1% | ||
| Q2 25 | 1.1% | — | ||
| Q1 25 | 2.0% | — | ||
| Q4 24 | 1.6% | — | ||
| Q3 24 | 2.4% | 0.0% | ||
| Q2 24 | 1.4% | 0.2% | ||
| Q1 24 | 2.3% | 0.0% |
| Q4 25 | 2.81× | — | ||
| Q3 25 | 1.52× | 0.56× | ||
| Q2 25 | 1.48× | — | ||
| Q1 25 | 0.78× | — | ||
| Q4 24 | 0.43× | — | ||
| Q3 24 | 1.85× | — | ||
| Q2 24 | 1.62× | — | ||
| Q1 24 | 0.71× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CSW
| Contractor Solutions Segment | $166.3M | 71% |
| Specialized Reliability Solutions Segment | $38.2M | 16% |
| Engineered Building Solutions Segment | $28.5M | 12% |
TVTX
| FILSPARI | $103.3M | 80% |
| Tiopronin Products | $23.3M | 18% |
| License | $3.1M | 2% |
